<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091777</url>
  </required_header>
  <id_info>
    <org_study_id>GDC-229-002</org_study_id>
    <nct_id>NCT03091777</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gage Development Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gage Development Company, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to compare the safety and efficacy of GDC-229 (test drug)
      against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to
      establish that these two drugs work better than placebo in subjects with BV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Resolution of clinical signs and symptoms</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">871</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-229 gel applied vaginally as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GDC-229 Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-229</intervention_name>
    <description>GDC-229 is a vaginal gel.</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Vaginal Gel 0.75%</intervention_name>
    <description>Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
    <arm_group_label>Reference Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive arm of the study</description>
    <arm_group_label>Vehicle Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-pregnant female aged ≥ 18 years who is in good general health

          2. Diagnosis of BV

          3. Willing to refrain from using any intravaginal product (e.g., spermicide, tampon,
             douche, feminine deodorant spray, diaphragm, vaginal ring birth control, or condom
             with spermicide or insertion into the vagina of any drug or non-drug product during
             treatment), other than study treatment for the duration of the trial

          4. Subjects of childbearing potential who have a negative urine pregnancy test at the
             Entry Visit (Visit 1) and agree to use an acceptable form of birth control throughout
             the study

          5. Able to understand and willing to sign the informed consent form (ICF) and able to
             comply with the requirements of the protocol

        Exclusion Criteria:

          1. History of alcohol or substance abuse

          2. Experienced a clinically significant medical event within 90 days

          3. Abnormal pap or high risk human papillomavirus (HPV)

          4. History or presence of clinically significant central nervous system (CNS),
             cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,
             immunologic, gynecologic, dermatologic, neurologic, oncologic, or psychiatric disease

          5. Pregnant, lactating, or planning to become pregnant or breastfeed during the study
             period

          6. Primary or secondary immunodeficiency

          7. Evidence of any vulvovaginitis at screening other than BV

          8. History of hypersensitivity or allergy to metronidazole, parabens, other
             nitroimidazole derivatives, or other ingredients of the GDC 229 (metronidazole 0.75%
             vaginal gel), metronidazole 0.75% vaginal gel (Oceanside Pharmaceuticals), or vehicle
             gel

          9. Participating in another clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Non-pregnant female aged ≥ 18 years who is in good general health</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>vaginal infection</keyword>
  <keyword>BV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

